title: Interview: Investigating immunomodulators among the Actinomycetales. Interview by Hannah Wilson.
abstract: John L Stanford speaks to Hannah Wilson, Assistant Commissioning Editor John L Stanford is Chief Scientific Officer at BioEos Ltd (Kent, UK). Dr Stanford began his career as a senior lecturer and then reader in microbiology at Middlesex Hospital Medical School (London, UK), then University College London Medical School, where he became Professor in Medical Microbiology and Head of Department in 1997. He retired and became Professor Emeritus in 2004. Dr Stanford's career has been devoted to research into mycobacteria, the diseases that they cause and the practical uses of this research. His special interest in recent years has been the development of bacterial immunotherapeutics for a range of diseases including tuberculosis and cancer. Dr Stanford was one of the founding directors of Stanford Rook Ltd (London) and of BioEos Ltd, where he remains a director. He also played a part in the founding of Immodulon Therapeutics Ltd (London) and of a new company, ActinoPharma Ltd (London), and has published more than 200 peer-reviewed scientific papers.
authors: John L
authors: JL
authors: Stanford
mesh_terms: D000192:Actinomycetales / Q000145:classification* / Q000276:immunology; D000818:Animals; D006801:Humans; D056747:Immunomodulation; D007167:Immunotherapy / Q000379:methods*; D009369:Neoplasms / Q000276:immunology / Q000628:therapy; D009170:Nontuberculous Mycobacteria / Q000276:immunology*; D014376:Tuberculosis / Q000276:immunology / Q000628:therapy